Rare Disease Focus Target accounts should consider collaborations or in-licensing partnerships for ATryn and its expanding applications, emphasizing hereditary antithrombin deficiency and potential expansion through PRESERVE-1 for early onset preeclampsia.

Clinical Pipeline Leverage ongoing Phase 3 PRESERVE-1 trial insights to position rEVO Biologics as a partner for obstetric clinics and specialized hospitals seeking innovative therapies for high-need patient populations.

Strategic Relationship Position as a boutique biopharma with strong parent company backing (LFB Biotechnologies) to engage mid-market biotech and specialty pharma distributors seeking differentiated biologics with proven manufacturing capabilities.

Geographic Fit Emphasize Boston-area presence and proximity to academic medical centers for collaborative research, clinical trials recruitment, and early-access programs in the U.S. Northeast market.

Commercial Readiness Offer customized manufacturing and supply-chain solutions for rare-disease products, including regulatory support, to potential partners seeking reliable biopharma manufacturing and secondary services for niche indications.